I didn't know about this.
I wonder if this could be a significant catalyst. It's certainly more difficult (for me) to readily figure how any news could be monetized over the next 12mos.
This question is most critical, and most in question, for protection afforded to the infants of those in the "pregnant-mothers" trial. Otherwise, the effectiveness has to last six months to cover the season. BTW, several times = "tenfold" . Erck was, I guess, legally limited by what he could imply. For the effectiveness in infants, post partum, set the bar at 3mos. for success but it sounds like he's hoping for 6 as well.
Trials in India are cheap.
I still wonder why the relationship with Cadilla seems so...vestigial to management post-Rahul. Here's a country that has a market more than double the EU and US combined (the exchange rate, and general economics mitigates that a bit), with PIII "seasonal" trial all but complete. Not to mention a rabies vaccine in the country with the biggest problem. There was a one-sentence comment by not-Rahul on this after the the last(?) question during the CC - but it was loaded. Something like 'good question, then 'we we will have a lot to say about these developments soon'...
And ... with your later post, you are proven nothing more than a shill (if there really was any question).
Why does anyone answer these less-than-meaningless posts?
You're putting pennies in his greasy pockets.
$4-5? You're either talking out of your adz or ...
Show me one example of a company (biotech) that has a similar profile and is below $8
Point taken. But there is a high %age of near-term catalysts: Funding, safety/immunogenicity ebola (Downunder), and seasonal Flu vax results due this Q being "the big one".
Very big sales. followed by tick's up. Read into it what you may but it might happen tomorrow as well. After any announcement tomorrow afternoon is the real question, one that has too many variables for me....
I find those Fed testimonies entertaining, just for the verbal gymnastics into absurdity. Greenspan was the best and Yellen is better than Bern(hackie). I'm sure it's designed that way to confuse the numbskull half on the committee, to help cut down on serious grilling...
...and I admit it too. And, not knowing what I know now, I would have the same opinion again.
There's is a new technology that will provide, at least one, probably several new "platforms" for antibiotics. Kim Lewis at ...Norteastern(?) has created a "diffuser" that can grow exclusively one form of bacteria in amounts large enough to study in a lab. Most antibiotics are derived from several of the myriad of bacteria that grow in soil. She's created a semipermeable medium that can house a bacteria to be grow after being shoved in the ground-as-the-medium.
Very exciting, probably easily Googlable...